Cargando…
Lipid Nanocarriers for Hyperproliferative Skin Diseases
SIMPLE SUMMARY: Different drugs, including antiproliferative and corticosteroids in general, are recommended for the treatment of hyperproliferative skin diseases (HSD). The effectiveness of many of these drugs is limited due to their low solubility in water and low penetration in the skin. The load...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615830/ https://www.ncbi.nlm.nih.gov/pubmed/34830774 http://dx.doi.org/10.3390/cancers13225619 |
_version_ | 1784604200436498432 |
---|---|
author | Souto, Eliana B. de Souza, Ana L. R. dos Santos, Fernanda K. Sanchez-Lopez, Elena Cano, Amanda Zielińska, Aleksandra Staszewski, Rafał Karczewski, Jacek Gremião, Maria P. D. Chorilli, Marlus |
author_facet | Souto, Eliana B. de Souza, Ana L. R. dos Santos, Fernanda K. Sanchez-Lopez, Elena Cano, Amanda Zielińska, Aleksandra Staszewski, Rafał Karczewski, Jacek Gremião, Maria P. D. Chorilli, Marlus |
author_sort | Souto, Eliana B. |
collection | PubMed |
description | SIMPLE SUMMARY: Different drugs, including antiproliferative and corticosteroids in general, are recommended for the treatment of hyperproliferative skin diseases (HSD). The effectiveness of many of these drugs is limited due to their low solubility in water and low penetration in the skin. The loading of these drugs in lipid nanocarriers, such as lipid nanoparticles and liposomes, has been considered as a successful solution to improve the drug bioavailability through the skin, to control their release kinetics and thus reduce the risk of potential side effects. In this work, we discuss the use of lipid nanocarriers loading drugs against HSD. ABSTRACT: Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD. |
format | Online Article Text |
id | pubmed-8615830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86158302021-11-26 Lipid Nanocarriers for Hyperproliferative Skin Diseases Souto, Eliana B. de Souza, Ana L. R. dos Santos, Fernanda K. Sanchez-Lopez, Elena Cano, Amanda Zielińska, Aleksandra Staszewski, Rafał Karczewski, Jacek Gremião, Maria P. D. Chorilli, Marlus Cancers (Basel) Review SIMPLE SUMMARY: Different drugs, including antiproliferative and corticosteroids in general, are recommended for the treatment of hyperproliferative skin diseases (HSD). The effectiveness of many of these drugs is limited due to their low solubility in water and low penetration in the skin. The loading of these drugs in lipid nanocarriers, such as lipid nanoparticles and liposomes, has been considered as a successful solution to improve the drug bioavailability through the skin, to control their release kinetics and thus reduce the risk of potential side effects. In this work, we discuss the use of lipid nanocarriers loading drugs against HSD. ABSTRACT: Hyperproliferative skin diseases (HSD) are a group of diseases that include cancers, pre-cancerous lesions and diseases of unknown etiology that present different skin manifestations in terms of the degree and distribution of the injuries. Anti-proliferative agents used to treat these diseases are so diverse, including 5-aminolevulinic acid, 5-fluorouracil, imiquimod, methotrexate, paclitaxel, podophyllotoxin, realgar, and corticosteroids in general. These drugs usually have low aqueous solubility, which consequently decreases skin permeation. Thus, their incorporation in lipid nanocarriers has been proposed with the main objective to increase the effectiveness of topical treatment and reduce side effects. This manuscript aims to describe the advantages of using lipid nanoparticles and liposomes that can be used to load diversity of chemically different drugs for the treatment of HSD. MDPI 2021-11-10 /pmc/articles/PMC8615830/ /pubmed/34830774 http://dx.doi.org/10.3390/cancers13225619 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Souto, Eliana B. de Souza, Ana L. R. dos Santos, Fernanda K. Sanchez-Lopez, Elena Cano, Amanda Zielińska, Aleksandra Staszewski, Rafał Karczewski, Jacek Gremião, Maria P. D. Chorilli, Marlus Lipid Nanocarriers for Hyperproliferative Skin Diseases |
title | Lipid Nanocarriers for Hyperproliferative Skin Diseases |
title_full | Lipid Nanocarriers for Hyperproliferative Skin Diseases |
title_fullStr | Lipid Nanocarriers for Hyperproliferative Skin Diseases |
title_full_unstemmed | Lipid Nanocarriers for Hyperproliferative Skin Diseases |
title_short | Lipid Nanocarriers for Hyperproliferative Skin Diseases |
title_sort | lipid nanocarriers for hyperproliferative skin diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615830/ https://www.ncbi.nlm.nih.gov/pubmed/34830774 http://dx.doi.org/10.3390/cancers13225619 |
work_keys_str_mv | AT soutoelianab lipidnanocarriersforhyperproliferativeskindiseases AT desouzaanalr lipidnanocarriersforhyperproliferativeskindiseases AT dossantosfernandak lipidnanocarriersforhyperproliferativeskindiseases AT sanchezlopezelena lipidnanocarriersforhyperproliferativeskindiseases AT canoamanda lipidnanocarriersforhyperproliferativeskindiseases AT zielinskaaleksandra lipidnanocarriersforhyperproliferativeskindiseases AT staszewskirafał lipidnanocarriersforhyperproliferativeskindiseases AT karczewskijacek lipidnanocarriersforhyperproliferativeskindiseases AT gremiaomariapd lipidnanocarriersforhyperproliferativeskindiseases AT chorillimarlus lipidnanocarriersforhyperproliferativeskindiseases |